Corline Biomedical AB

OM:CLBIO Rapport sur les actions

Capitalisation boursière : SEK 247.1m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Corline Biomedical Croissance future

Future contrôle des critères 6/6

Corline Biomedical is forecast to grow earnings and revenue by 114.8% and 68.2% per annum respectively. EPS is expected to grow by 115.1% per annum. Return on equity is forecast to be 28.7% in 3 years.

Informations clés

114.8%

Taux de croissance des bénéfices

115.1%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices68.7%
Taux de croissance des recettes68.2%
Rendement futur des capitaux propres28.7%
Couverture par les analystes

Low

Dernière mise à jour03 May 2024

Mises à jour récentes de la croissance future

Recent updates

We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth

Mar 15
We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth

We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow

Nov 26
We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow

Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

Jun 22
Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth

Feb 16
We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth

Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth

Jun 14
Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth

Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation

Feb 28
Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation

Prévisions de croissance des bénéfices et des revenus

OM:CLBIO - Estimations futures des analystes et données financières antérieures (SEK Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202618111391991
12/31/2025602014211
12/31/202436-11-21-141
3/31/202431-4-37N/A
12/31/202336-2-101N/A
9/30/202337-1-12-2N/A
6/30/2023401-120N/A
3/31/2023384-16-5N/A
12/31/2022332-15-6N/A
9/30/2022311-14-2N/A
6/30/202223-3-15-6N/A
3/31/202219-6-16-6N/A
12/31/202117-7-14-5N/A
9/30/202115-6-12-6N/A
6/30/202113-6-12-7N/A
3/31/202114-6-12-6N/A
12/31/202015-7-14-5N/A
9/30/202014-9-20-7N/A
6/30/202014-9-20-9N/A
3/31/202014-9-20-11N/A
12/31/201912-10-19-14N/A
9/30/201911-9-17-17N/A
6/30/201911-9-5-5N/A
3/31/201910-8-5-4N/A
12/31/201810-7-5-4N/A
9/30/201817-7-8-6N/A
6/30/201816-6-18-15N/A
3/31/201815-7-19-16N/A
12/31/201716-8N/A-5N/A
9/30/20177-8N/A-2N/A
6/30/20179-8N/A-2N/A
3/31/201710-6N/A1N/A
12/31/20169-5N/A-7N/A
9/30/20168-6N/A-5N/A
6/30/20167-6N/A-4N/A
3/31/20165-7N/A-5N/A
12/31/20154-6N/A-4N/A
12/31/20144-3N/A-2N/A
12/31/20134-2N/AN/AN/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: CLBIO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.1%).

Bénéfices vs marché: CLBIO is forecast to become profitable over the next 3 years, which is considered above average market growth.

Croissance élevée des bénéfices: CLBIO is expected to become profitable in the next 3 years.

Chiffre d'affaires vs marché: CLBIO's revenue (68.2% per year) is forecast to grow faster than the Swedish market (1.1% per year).

Croissance élevée des revenus: CLBIO's revenue (68.2% per year) is forecast to grow faster than 20% per year.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: CLBIO's Return on Equity is forecast to be high in 3 years time (28.7%)


Découvrir les entreprises en croissance